FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2464724361> ?p ?o ?g. }

• W2464724361 endingPage "e0157742" @default.
• W2464724361 startingPage "e0157742" @default.
• W2464724361 abstract "Background The HIV epidemic in the United States (US) disproportionately affects gay, bisexual, and other men who have sex with men (MSM). Pre-exposure prophylaxis (PrEP) using co-formulated tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) has demonstrated high efficacy in reducing HIV incidence among MSM. However, low adherence was reported in major efficacy trials and may present a substantial barrier to successful PrEP implementation. Rates of adherence to PrEP in “real-world” clinical settings in the US remain largely unknown. Methods We reviewed demographic and clinical data for the first 50 patients to enroll in a clinical PrEP program in Providence, Rhode Island. We analyzed self-reported drug adherence as well as drug concentrations in dried blood spots (DBS) from patients who attended either a three- or six-month follow-up appointment. We further assessed drug concentrations and the resistance profile of a single patient who seroconverted while taking PrEP. Results Of the first 50 patients to be prescribed PrEP, 62% attended a follow-up appointment at three months and 38% at six months. Of those who attended an appointment at either time point (70%, n = 35), 92% and 95% reported taking ±4 doses/week at three and six months, respectively. Drug concentrations were performed on a random sample of 20 of the 35 patients who attended a follow-up appointment. TDF levels consistent with ±4 doses/week were found in 90% of these patients. There was a significant correlation between self-reported adherence and drug concentrations (r = 0.49, p = 0.02). One patient who had been prescribed PrEP seroconverted at his three-month follow-up visit. The patient’s drug concentrations were consistent with daily dosing. Population sequencing and ultrasensitive allele-specific PCR detected the M184V mutation, but no other TDF- or FTC-associated mutations, including those present as minor variants. Conclusion In this clinical PrEP program, adherence was high, and self-reported drug adherence accurately reflected drug concentrations as measured by DBS." @default.
• W2464724361 created "2016-07-22" @default.
• W2464724361 creator A5004723861 @default.
• W2464724361 creator A5009650301 @default.
• W2464724361 creator A5024140214 @default.
• W2464724361 creator A5025150770 @default.
• W2464724361 creator A5031426841 @default.
• W2464724361 creator A5037897962 @default.
• W2464724361 creator A5040068767 @default.
• W2464724361 creator A5054571824 @default.
• W2464724361 creator A5057458575 @default.
• W2464724361 creator A5074370380 @default.
• W2464724361 date "2016-06-22" @default.
• W2464724361 modified "2023-10-16" @default.
• W2464724361 title "Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting" @default.
• W2464724361 cites W1413161224 @default.
• W2464724361 cites W1998773972 @default.
• W2464724361 cites W2039503871 @default.
• W2464724361 cites W2044369525 @default.
• W2464724361 cites W2052123269 @default.
• W2464724361 cites W2054763716 @default.
• W2464724361 cites W2082146526 @default.
• W2464724361 cites W2086085111 @default.
• W2464724361 cites W2103920597 @default.
• W2464724361 cites W2117057469 @default.
• W2464724361 cites W2132977017 @default.
• W2464724361 cites W2135466424 @default.
• W2464724361 cites W2138391170 @default.
• W2464724361 cites W2150644408 @default.
• W2464724361 cites W2162226934 @default.
• W2464724361 cites W2168251450 @default.
• W2464724361 cites W2171609071 @default.
• W2464724361 cites W2173821673 @default.
• W2464724361 cites W2189900404 @default.
• W2464724361 cites W2286815984 @default.
• W2464724361 cites W2319917590 @default.
• W2464724361 cites W2334368177 @default.
• W2464724361 cites W2427561303 @default.
• W2464724361 doi "https://doi.org/10.1371/journal.pone.0157742" @default.
• W2464724361 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4917105" @default.
• W2464724361 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27333000" @default.
• W2464724361 hasPublicationYear "2016" @default.
• W2464724361 type Work @default.
• W2464724361 sameAs 2464724361 @default.
• W2464724361 citedByCount "59" @default.
• W2464724361 countsByYear W24647243612016 @default.
• W2464724361 countsByYear W24647243612017 @default.
• W2464724361 countsByYear W24647243612018 @default.
• W2464724361 countsByYear W24647243612019 @default.
• W2464724361 countsByYear W24647243612020 @default.
• W2464724361 countsByYear W24647243612021 @default.
• W2464724361 countsByYear W24647243612022 @default.
• W2464724361 countsByYear W24647243612023 @default.
• W2464724361 crossrefType "journal-article" @default.
• W2464724361 hasAuthorship W2464724361A5004723861 @default.
• W2464724361 hasAuthorship W2464724361A5009650301 @default.
• W2464724361 hasAuthorship W2464724361A5024140214 @default.
• W2464724361 hasAuthorship W2464724361A5025150770 @default.
• W2464724361 hasAuthorship W2464724361A5031426841 @default.
• W2464724361 hasAuthorship W2464724361A5037897962 @default.
• W2464724361 hasAuthorship W2464724361A5040068767 @default.
• W2464724361 hasAuthorship W2464724361A5054571824 @default.
• W2464724361 hasAuthorship W2464724361A5057458575 @default.
• W2464724361 hasAuthorship W2464724361A5074370380 @default.
• W2464724361 hasBestOaLocation W24647243611 @default.
• W2464724361 hasConcept C120665830 @default.
• W2464724361 hasConcept C121332964 @default.
• W2464724361 hasConcept C126322002 @default.
• W2464724361 hasConcept C142462285 @default.
• W2464724361 hasConcept C2776939746 @default.
• W2464724361 hasConcept C2776983459 @default.
• W2464724361 hasConcept C2779496540 @default.
• W2464724361 hasConcept C2779778239 @default.
• W2464724361 hasConcept C2780035454 @default.
• W2464724361 hasConcept C2993143319 @default.
• W2464724361 hasConcept C3013748606 @default.
• W2464724361 hasConcept C512399662 @default.
• W2464724361 hasConcept C535046627 @default.
• W2464724361 hasConcept C61511704 @default.
• W2464724361 hasConcept C71924100 @default.
• W2464724361 hasConcept C98274493 @default.
• W2464724361 hasConceptScore W2464724361C120665830 @default.
• W2464724361 hasConceptScore W2464724361C121332964 @default.
• W2464724361 hasConceptScore W2464724361C126322002 @default.
• W2464724361 hasConceptScore W2464724361C142462285 @default.
• W2464724361 hasConceptScore W2464724361C2776939746 @default.
• W2464724361 hasConceptScore W2464724361C2776983459 @default.
• W2464724361 hasConceptScore W2464724361C2779496540 @default.
• W2464724361 hasConceptScore W2464724361C2779778239 @default.
• W2464724361 hasConceptScore W2464724361C2780035454 @default.
• W2464724361 hasConceptScore W2464724361C2993143319 @default.
• W2464724361 hasConceptScore W2464724361C3013748606 @default.
• W2464724361 hasConceptScore W2464724361C512399662 @default.
• W2464724361 hasConceptScore W2464724361C535046627 @default.
• W2464724361 hasConceptScore W2464724361C61511704 @default.
• W2464724361 hasConceptScore W2464724361C71924100 @default.
• W2464724361 hasConceptScore W2464724361C98274493 @default.
• W2464724361 hasFunder F4320308573 @default.

• next